232 related articles for article (PubMed ID: 17408854)
1. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
2. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?
Sancesario GM; Esposito Z; Nuccetelli M; Bernardini S; Sorge R; Martorana A; Federici G; Bernardi G; Sancesario G
Exp Neurol; 2010 Jun; 223(2):371-6. PubMed ID: 19664624
[TBL] [Abstract][Full Text] [Related]
3. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko D
J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
[TBL] [Abstract][Full Text] [Related]
6. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
7. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
8. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
Wiltfang J; Esselmann H; Bibl M; Hüll M; Hampel H; Kessler H; Frölich L; Schröder J; Peters O; Jessen F; Luckhaus C; Perneczky R; Jahn H; Fiszer M; Maler JM; Zimmermann R; Bruckmoser R; Kornhuber J; Lewczuk P
J Neurochem; 2007 May; 101(4):1053-9. PubMed ID: 17254013
[TBL] [Abstract][Full Text] [Related]
9. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
12. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
15. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
17. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
[TBL] [Abstract][Full Text] [Related]
18. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
20. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]